NEW YORK (GenomeWeb) – Early clinical trial data on Merck KGaA's c-Met inhibitor tepotinib suggests the drug may be efficacious against lung and liver tumors driven by alterations in the MET oncogene.
The development program for the drug in a molecularly defined non-small cell lung cancer subpopulation includes a companion diagnostic strategy involving tests that can gauge MET exon-14-skipping mutations in tumor tissue and blood.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
